Symptra is built around GLP-1 medications, prescription drugs that change biology in meaningful ways. The articles in our library exist to help you understand what is happening in your body, recognize what is normal, and know when to talk to your doctor. That is a responsibility we take seriously. This page explains how we do that work.

Who writes Symptra articles.

Articles are written by the Symptra Editorial Team, the same people who design and build the app. We are product researchers, designers, and engineers with a long-running interest in this space. We are not physicians, and we do not represent ourselves as ones.

That is a deliberate choice. The honest version is more useful to you than a fabricated medical persona would be.

In short
Symptra articles are research summaries, not medical advice. Every clinical claim links to a primary source. Anything that sounds like advice is a description of strategies people commonly try, discussed with your healthcare provider, not prescribed by us.

Where the information comes from.

Every clinical claim in a Symptra article is traceable to one of three source types, in this order of priority:

  1. FDA prescribing information. For each GLP-1 medication we cover (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, Victoza, Trulicity) the official FDA label is the first reference for approved doses, titration schedules, contraindications and labeled side-effect rates.
  2. Peer-reviewed clinical trials and meta-analyses. We rely on landmark studies (STEP 1, SELECT, SURMOUNT, TRIUMPH) and on systematic reviews indexed in PubMed Central, the New England Journal of Medicine, the Lancet, Nature, JAMA and similar journals. Every quantitative figure in an article ("80% of patients maintain weight on lower doses", "5.3% alopecia at >20% weight loss") traces to one of these sources.
  3. Aggregated community experience. We read GLP-1 communities (particularly on Reddit) to understand what real users find confusing, scary, or unhelpful in clinical literature. Patterns we surface here ("food noise quieting in week one", "metallic taste with the pill", "magnesium citrate works when stool softeners don't") are documented across hundreds of user posts. We do not present community wisdom as medical guidance. We present it as "many people describe…" with a link to the underlying clinical evidence whenever one exists.

A source document we maintain internally, GLP-1 Verified Medical Sources, contains roughly 80 primary citations across 18 topic areas. Each article in the library is written against this document; the citations you see at the bottom of each article are a subset of that working bibliography.

Our quality bar.

Before an article is published it has to clear four checks:

  1. Every quantitative claim is sourced. If we cannot link a percentage, dose, timeline or risk figure to a primary source, the sentence comes out.
  2. No drug-specific advice. We do not tell anyone what to take, what to switch to, what dose to use, or when to stop. We describe what a class of medications does and how clinical trials measured it.
  3. "Talk to your provider" prompts at every decision point. When the right next step depends on individual context (labs, history, contraindications, pregnancy, mental-health background) the article says so explicitly.
  4. Plain language. If a sentence reads like a journal abstract, it gets rewritten until a person on their second week of GLP-1 can follow it.

How often we update.

The GLP-1 landscape moves quickly. Phase 3 results, FDA actions, new safety signals, revised guidelines and label updates appear several times a year. Our cadence:

What this is not.

Symptra articles are not medical advice. Specifically, none of the content on this site is intended to:

If you are deciding whether to start, switch, or stop a GLP-1 medication, that decision belongs in a clinic, not in a phone app. We can help you arrive at that conversation better-informed.

Corrections.

If you find a factual error in any Symptra article (an outdated citation, a misread percentage, a study we should have known about) write to hello@appix.fun with the article URL and the correction. We acknowledge corrections within five business days and update the article with a visible note at the bottom describing what changed and when.

What changes when we can.

The single biggest upgrade we could make is adding a named medical reviewer: a registered dietitian or physician with public credentials who signs off on each article. We have not done this yet because doing it credibly is more expensive than our current operating budget allows, and doing it incredibly (faking it) would be worse than not doing it at all. When we can, this is the change that comes first.

This page is part of the Symptra editorial policy. Articles in our library are independent and not sponsored by any pharmaceutical manufacturer. Symptra is not affiliated with Novo Nordisk or Eli Lilly. Trademarks belong to their respective owners.